Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Scott Kellen | M | 59 | 6 years | |
| Paul Papi | M | - | 8 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Philip M. Rees | M | 62 |
The University of North Carolina at Asheville
| 8 years |
| Dawson J. Reimer | M | 53 | 5 years | |
| Zhen Yu Xiao | M | 50 | - | |
| Peter S. Ringrose | M | 78 |
Bristol-Myers Squibb Pharmaceutical Research Institute
| 5 years |
| Xin Ming Mu | M | 67 |
The University of North Carolina at Asheville
| 3 years |
| Kevin W. Markham | M | - |
The University of North Carolina at Asheville
| 6 years |
| Mark Williams | M | 52 | 11 years | |
| Rajiv Khosla | M | 62 |
Orasi Medical, Inc.
 Orasi Medical, Inc. Medical/Nursing ServicesHealth Services Orasi Medical, Inc. is a privately held, early stage medical device company engaged in the development and commercialization of technology to diagnose and monitor neurological diseases. They have developed a painless, non-invasive test that takes less than ten (10) minutes to administer and, based on the results of its current research, is more accurate than current clinical practice. Initially, its aim is to develop the first FDA cleared test for the diagnosis of Alzheimer's disease. In addition, they are developing products for pharmaceutical companies to measure treatment effect and reduce the cost of clinical drug trials for neurological diseases. Ultimately, its long-term goal is to set the standard of care for diagnosis and monitoring of major neurological diseases such as Alzheimer's disease, multiple sclerosis, Parkinson's, autism, depression and attention deficit hyperactivity disorder (ADHD). | 1 years |
| Perry B. Molinoff | M | 84 |
Bristol-Myers Squibb Pharmaceutical Research Institute
| 6 years |
| Roy J. Ramthun | M | - |
The University of North Carolina at Asheville
| 1 years |
| James R. Hampton | M | - |
The University of North Carolina at Asheville
| 4 years |
| Charles John Dean | M | - |
The University of North Carolina at Asheville
| 1 years |
| Safwan Zuhair Abdul Ghani Al-Amad | M | 64 |
The University of North Carolina at Asheville
| 4 years |
| Susan L. Gottshall | F | - |
Algos Therapeutics, Inc.
 Algos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Algos PreClinical Services, Inc. engages in preclinical pain drug development. It specializes in preclinical in vivo pain research and program consulting. The company was founded by Susanne C. Dvorak and Todd C. Verdoorn in 2003 and is headquartered in Roseville, MN. | - |
| John Crockett | M | 59 |
The University of North Carolina at Asheville
| 4 years |
| Dave Hartzell | M | 68 |
The University of North Carolina at Asheville
| 3 years |
| Thomas W. Griffin | M | - |
Bristol-Myers Squibb Pharmaceutical Research Institute
| 7 years |
| Maria Kenny | F | 57 |
The University of North Carolina at Asheville
| 4 years |
| Susanne Dvorak | F | - |
Algos Therapeutics, Inc.
Algos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Algos PreClinical Services, Inc. engages in preclinical pain drug development. It specializes in preclinical in vivo pain research and program consulting. The company was founded by Susanne C. Dvorak and Todd C. Verdoorn in 2003 and is headquartered in Roseville, MN. | - |
| Christopher O. Robbins | M | 55 |
The University of North Carolina at Asheville
| 4 years |
| Edison Liu | M | - |
The University of North Carolina at Asheville
| 9 years |
| Joe Beaman | M | - |
The University of North Carolina at Asheville
| 4 years |
| Robert F. Butz | M | - |
Orasi Medical, Inc.
Orasi Medical, Inc. Medical/Nursing ServicesHealth Services Orasi Medical, Inc. is a privately held, early stage medical device company engaged in the development and commercialization of technology to diagnose and monitor neurological diseases. They have developed a painless, non-invasive test that takes less than ten (10) minutes to administer and, based on the results of its current research, is more accurate than current clinical practice. Initially, its aim is to develop the first FDA cleared test for the diagnosis of Alzheimer's disease. In addition, they are developing products for pharmaceutical companies to measure treatment effect and reduce the cost of clinical drug trials for neurological diseases. Ultimately, its long-term goal is to set the standard of care for diagnosis and monitoring of major neurological diseases such as Alzheimer's disease, multiple sclerosis, Parkinson's, autism, depression and attention deficit hyperactivity disorder (ADHD). | 1 years |
| Richard Bebout | M | - |
The University of North Carolina at Asheville
| 3 years |
| Stephen R. Daniels | M | - |
The University of North Carolina at Asheville
| 3 years |
| David J. Laing | M | - |
The University of North Carolina at Asheville
| 3 years |
| Ross McMeekin | M | - |
The University of North Carolina at Asheville
| 4 years |
| Gail Hunter | F | - |
The University of North Carolina at Asheville
| 4 years |
| Dan Fitz | M | 64 |
The University of North Carolina at Asheville
| 3 years |
| Soo-Geun Kwak | M | 70 |
The University of North Carolina at Asheville
| 3 years |
| Alice Carmichael Richey | F | - |
The University of North Carolina at Asheville
| 3 years |
| Jeff Cardell | M | - |
The University of North Carolina at Asheville
| 3 years |
| Scott Biller | M | 68 |
Bristol-Myers Squibb Pharmaceutical Research Institute
| 2 years |
| Faisal Al Kurdi | M | - |
The University of North Carolina at Asheville
| 1 years |
| Stephen Woody | M | 61 |
The University of North Carolina at Asheville
| 4 years |
| Sydney A. Gilman | M | 72 | - | |
| Sheila Leigh King | F | - |
The University of North Carolina at Asheville
| 4 years |
| Sami Mohammed Abdullah Othman Al-Dakhil | M | - |
The University of North Carolina at Asheville
| 4 years |
| Hong-Gil Nam | M | - |
The University of North Carolina at Asheville
| 3 years |
| Timothy C. McCoy | M | - |
The University of North Carolina at Asheville
| 4 years |
| Lawrence S. Block | M | 57 |
The University of North Carolina at Asheville
| 4 years |
| David T. Hagerty | M | 69 |
Bristol-Myers Squibb Pharmaceutical Research Institute
| 9 years |
| David Lee Thompson | M | - |
The University of North Carolina at Asheville
| 2 years |
| Clay Siegall | M | 63 |
Bristol-Myers Squibb Pharmaceutical Research Institute
| 6 years |
| Harry W. Alcorn | M | 68 | 4 years | |
| Leon E. Rosenberg | M | 90 |
Bristol-Myers Squibb Pharmaceutical Research Institute
| 6 years |
| David Craver | M | - |
The University of North Carolina at Asheville
| 4 years |
| Paige Camille Henderson | F | - |
The University of North Carolina at Asheville
| 4 years |
| Campbell Ort Jenkins | M | - |
The University of North Carolina at Asheville
| 4 years |
| Scott Hyney | M | - |
The University of North Carolina at Asheville
| 2 years |
| Carter Newbold | M | 58 |
The University of North Carolina at Asheville
| 4 years |
| Alexander Duncan McLean | M | - |
The University of North Carolina at Asheville
| 4 years |
| Mark E. Davis | M | - |
The University of North Carolina at Asheville
| 4 years |
| David J. Lewis | M | - |
The University of North Carolina at Asheville
| 4 years |
| Peter Hartwell Bowles | M | 55 |
The University of North Carolina at Asheville
| 4 years |
| Jack P. Devereaux | M | - |
The University of North Carolina at Asheville
| 1 years |
| David Gardner | M | - |
The University of North Carolina at Asheville
| 4 years |
| R. Mason Bayler | M | - |
The University of North Carolina at Asheville
| 4 years |
| Scott Boulware | M | - |
The University of North Carolina at Asheville
| 4 years |
| D. Stuart Lindley | M | - |
The University of North Carolina at Asheville
| 4 years |
| Brad Conger | M | - |
The University of North Carolina at Asheville
| 4 years |
| David A. Gurvey | M | - | 3 years | |
| Jeffery Kelly | M | 63 |
The University of North Carolina at Asheville
| 3 years |
| Victor J. Strecher | M | - |
The University of North Carolina at Asheville
| 10 years |
| Lorelei D. Davis | M | - |
The University of North Carolina at Asheville
| 3 years |
| John L. Monroe | M | - |
The University of North Carolina at Asheville
| 3 years |
| Kenneth Eheman | M | - |
The University of North Carolina at Asheville
| 4 years |
| Boyd A. Rogers | M | 74 |
The University of North Carolina at Asheville
| 2 years |
| Terence J. Watterson | M | - |
The University of North Carolina at Asheville
| 3 years |
| Milind Deshpande | M | 67 |
Bristol-Myers Squibb Pharmaceutical Research Institute
| 10 years |
| W. Chad Nesbit | M | - |
The University of North Carolina at Asheville
| 4 years |
| Sesha Neervannan | M | 56 |
Bristol-Myers Squibb Pharmaceutical Research Institute
| 5 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 74 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Todd A. Verdoorn
- Personal Network
